Zhejiang Shouxiangu Pharmaceutical Co., Ltd. (SHSE:603896) agreed to acquire Hangzhou Yunhe Hengli Commercial Real Estate Co., Ltd from Hangzhou Yunhe Group Construction Management Co., Ltd. for CNY 0.001 million on July 17, 2023. On august 21, 2023 Zhejiang Shouxiangu Pharmaceutical Co., Ltd. and Hangzhou Yunhe Group Construction Management Co., Ltd signed the share transfer agreement. Zhejiang Shouxiangu Pharmaceutical's board of director's approved the transaction.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
27.46 CNY | -0.36% | -0.15% | -14.83% |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-14.83% | 758M | |
+43.96% | 6.32B | |
-15.56% | 4.49B | |
-6.52% | 3.3B | |
+5.47% | 3.19B | |
-0.76% | 2.6B | |
+56.34% | 2.05B | |
-4.11% | 1.77B | |
+2.93% | 1.7B | |
-8.02% | 1.63B |
- Stock Market
- Equities
- 603896 Stock
- News Zhejiang Shouxiangu Pharmaceutical Co., Ltd.
- Zhejiang Shouxiangu Pharmaceutical Co., Ltd. agreed to acquire Hangzhou Yunhe Hengli Commercial Real Estate Co., Ltd from Hangzhou Yunhe Group Construction Management Co., Ltd. for CNY 0.001 million.